TF and prostate adenocarcinoma: Consequently, despite the 1639 TFs encoded in the human genome,[30] only a small fraction has been linked to PRAD and NEPC, leaving many critical regulators unidentified.[31] This gap, compounded by the predominant focus on a handful well‐characterized TFs, underscores the need for a more comprehensive approach to fully delineate the TF landscape in PCa, capturing both established and novel regulators implicated in tumor evolution and therapy resistance.